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ABSTRACT 
Background— Cardiovascular disease (CVD) risk scores that require laboratory testing  (e.g., cholesterol testing) 
are often used to identify high- and low-risk individuals for primary CVD prevention interventions, such as statin 
treatment. However, laboratory testing can be expensive and difficult to conduct in resource-limited settings. The 
aim of this study was to compare CVD risk characterization and evaluate the cost-effectiveness of non-laboratory-
based and laboratory-based CVD risk scores for adults in Tashkent City, Uzbekistan. 
Methods—CVD risk for 853 adults (376 men, 477 women) from Tashkent City, Uzbekistan was assessed using 
laboratory-based and non-laboratory-based scores calculated from 2002 Uzbekistan Health Examination Survey 
(UHES) data. Non-laboratory-based risk predictions were compared to the six laboratory-based scores (SCORE for 
high-risk and low-risk countries, three versions of Framingham risk scores, and CUORE) using Spearman rank 
correlation. The agreement of risk characterization for men was also evaluated by calculating the proportion of the 
male population equivalently characterized as “high” or “low” risk using either type of score. Using the UHES data, 
model populations of 10,000 men and 10,000 women were generated and used for cost-effectiveness modeling. A 
micro-simulation model that projected lifetime CVD-associated costs and quality-adjusted life years (QALYs) was 
used to calculate incremental cost-effectiveness ratios (ICERs) for non-laboratory and SCORE (for high risk 
countries) risk screening approaches.  
Results - The Spearman rank correlation coefficients for the laboratory-based and non-laboratory-based CVD risk 
scores ranged from 0.872-0.984 for men and 0.937-0.980 for women. The ICERs for the non-laboratory-based 
strategies on the efficient frontier (nondominated strategies) ranged from $843 to $6,551 for men and $6,249 to 
$16,193 for women. Almost all SCORE strategies for both men and women were dominated (higher cost and lower 
QALYs); the only exception had an ICER of $91,799 
Conclusions - For both men and women, there was a high correlation between the laboratory-based and non-
laboratory-based risk assessment methods. In men, there was also a high level of agreement in risk characterization 
between the laboratory-based and non-laboratory-based risk scores. It is cost-effective to use the non-laboratory 
based risk score to assess and then treat the top 1.60% of the male population who are at the highest risk for 
developing CVD (given a willingness to pay threshold of $5,150/QALY). No CVD screening is cost-effective for 
women in Uzbekistan. 
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INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death in Uzbekistan, accounting for 56% 
of all deaths in the country.1 The 2008 CVD and diabetes mortality rate in Uzbekistan was 718 
deaths per 100,000, for males and 564 deaths per 100,000 for females.1 Approximately half of all 
CVD-related deaths can be attributed to ischemic heart disease, while another quarter are due to 
cerebrovascular disease.2 Early detection and treatment of high-risk individuals could help 
reduce Uzbekistan’s CVD burden. Absolute CVD risk scores, such as Framingham and SCORE 
(Systematic COronary Risk Evaluation), can be used to calculate an individual’s CVD risk by 
assessing the synergistic effects of multiple risk factors.  
Since commonly used CVD risk scores include at least one laboratory-based input (i.e., total 
and/or HDL cholesterol), they can be expensive and difficult to conduct in resource-limited 
settings. Non-laboratory-based CVD risk scores can be an effective alternative to laboratory-
based risk scores. In this inexpensive non-laboratory-based risk prediction approach, body mass 
index (BMI) replaces total cholesterol and only CVD risk factors that can be assessed in 5-10 
minutes (such as sex, age, systolic blood pressure, smoking status, diabetes history, treatment for 
hypertension and BMI) are used as inputs.  
The non-laboratory-based risk score has been validated for the United States as an effective 
substitute for laboratory-based CVD risk scores.3 In previous studies, a high agreement in CVD 
risk characterization was also found between non-laboratory and laboratory-based risk scores in 
different South African populations.4 In order to further validate the exchangeability of the non-
laboratory-based score with laboratory-based scores in a developing setting, the two types of risk 
scores were compared using data from individuals living in Tashkent City, Uzbekistan.  
The objectives of this study were to compare the sex-specific CVD risk characterization of the 
non-laboratory-based score to six commonly used laboratory-based risk scores and to conduct a 
cost-effectiveness analysis (CEA) comparing SCORE (laboratory based-risk prediction 




Study Population  
The 2002 Uzbekistan Health Examination Survey (UHES) is the most recent nationally 
representative survey conducted by the Ministry of Health and Demographics Health Surveys 
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program.5 Among the 5,463 women and 2,333 men included in the UHES, this study focused on 
376 men between the ages of 25 and 59 and 477 women between the ages of 24 and 49 from 
Tashkent City, Uzbekistan. Individuals from other regions in Uzbekistan were excluded from our 
study because data on cholesterol levels (an input required to calculate laboratory-based scores) 
was unavailable.   
 
CVD Risk Scores  
The analyses on the comparison of absolute CVD risk scores were based the non-laboratory-
based risk score and six commonly used laboratory-based risk scores (Framingham 2008, two 
versions of Framingham 1991, SCORE for high- and low-risk countries and CUORE). Table-A1 
in the Appendix describes the study populations, inputs and outcomes that have been used for 
each score. Since SCORE is the CVD risk prediction method specifically developed for Europe 
and Central Asia, and Uzbekistan is considered a high CVD risk country, the main analysis was 
focused on comparing the SCORE prediction approach for high-risk countries to the non-
laboratory risk score.6  
 
Statistical Analysis for Comparative Assessment  
First, the individual-level risk scores were calculated using each of the six laboratory-based 
scores and the non-laboratory-based score. Individuals were assigned a rank for each risk score 
by sex. Then the Spearman rank correlation coefficients were computed comparing the non-
laboratory-based risk score to each of the laboratory-based risk scores to assess the agreement in 
rankings among all individuals.  
These ranks were also used to assess agreement in risk characterization for men comparing the 
non-laboratory-based score to each of the six laboratory based scores. Individuals were stratified 
using two cutoffs per European Society of Cardiology (ESCARDIO) guidelines: (1) individuals 
were characterized as “high” (10 year CVD risk measured by SCORE > 5%) or “moderate to 
low” risk; (2) individuals were characterized as “moderate to high” (10 year CVD risk measured 
by SCORE > 1%) risk or “low” risk.6 The percent agreement in risk characterization was 
determined by calculating the proportion of the male population characterized as the same risk 
status using both the non-laboratory-based risk score and the laboratory-based risk score. The 
agreement of risk characterization for women was not calculated. This was because the women 
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in our data were restricted to ages of 25-49 (men were between the ages of 25-59), and 
subsequently had very low CVD risk (ranging from 0.00% to 2.81% SCORE risk). 
 
Model Population for CEA  
Hypothetical populations of 10,000 men and 10,000 women were generated using a 
mathematical model, a random-number generator, probability distributions capturing the 
epidemiology of the study population and the existing UHES and population-level data from 
Uzbekistan. The distributions of age (years 25-74) in the model population were based on 
Uzbekistan’s sex-specific population distributions.7 Using these data, each of the 10,000 men 
and 10,000 women were assigned an age between 25 and 74.  
Once the sex-specific age distributions were determined, CVD risk factors (systolic blood 
pressure, total and HDL cholesterol, BMI, smoking status, diabetes history, and blood pressure 
medication use) were populated for every individual in the simulation. Stepwise regression and 
forward selection techniques were used to create sex-specific regressions for each CVD risk 
factor using UHES data (full data for all regressions except for those involving cholesterol, 
which was restricted to individuals in Tashkent City with cholesterol information collected). All 
regressions included age as an explanatory variable and some regressions also included other risk 
factors as explanatory variables (with prudent addition of squared terms). When creating the 
regressions for total cholesterol as the dependent variable, BMI was not included as an 
explanatory variable even though it was significant. The rationale for excluding this relationship 
was to make a conservative assumption by biasing the model against agreement in BMI and total 
cholesterol (and in effect biasing the model against agreement in non-laboratory-based and 
laboratory-based risk scores). Regressions were run using PROC REG or PROC LOGISITC in 
SAS Version 9.3. Continuous variables (BMI, total cholesterol, HDL cholesterol and systolic 
blood pressure) were predicted using the expected value from the regression as the mean and 
squared standard errors as the variance. Binary variables (smoking, diabetes, treatment for 
hypertension) were determined using the probability value from the logistic regression and 
random numbers. For example, if the probability that an individual smokes (based off of the 
regression) is .80, then he would be a smoker if his randomly assigned number was less than .80. 
Appendix-A2 provides more details on the different sex-specific regressions used for each CVD 
risk factor.  




The CEA model used in this study was based on a previously developed CVD micro-simulation 
model for the United States.8 The model structure (Figure 1) of the micro-simulation model is 
based on a CVD Markov model where CVD risk is assessed using Framingham (laboratory-
based) risk functions.9,10 In this model, all individuals begin in the disease-free (without 
treatment) state and are assessed for CVD risk using non-laboratory or laboratory-based risk 
scores every 5 years at primary care physician visits. Screening for CVD continues every 5 years 
until the individual is considered high-risk and receives treatment, experiences a stroke or 
coronary heart disease event, or dies. Details on the possible transitions in the micro-simulation 
model can be found in Appendix-A3.  
The input variables for this model were updated to reflect an Uzbekistani population (regional 
data and/or data from similar countries in the Central Asia region were used). This model 
assesses the cost-effectiveness of CVD screening strategies and statin decisions by projecting 
CVD-associated costs and health outcomes for an Uzbekistani population. Table A4 and Table 
A5 in the Appendix show the disease progression inputs and costs, utility and treatment inputs 




For the model-based CEA, the non-laboratory score was compared to SCORE for high-risk 
countries. A total of nine strategies with varying statin decision thresholds were evaluated (Table 
1). The non-lab cutoffs >40%, >30%, >20% and >10% result in 0.8%, 1.6%, 4.3% and 19.7% of 
the population being treated with statins respectively. The SCORE cutoffs > 7.5%, > 6.3%, 
>4.6% and > 1.6% correspond to the same proportions of the population treated. The cutoffs are 
different because the outcome SCORE predicts (fatal MI and stroke events) is more restrictive 
than the non-lab risk score outcome. The non-lab score predicts fatal and non-fatal MIs, strokes 
and other common events such as congestive heart failure and revascularization. 
The average-per-person costs and quality-adjusted life years (QALYs) were calculated for each 
strategy. After the strategies were ranked by cost, strongly dominated strategies (higher costs but 
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lower QALYs than competing strategies) were eliminated. Incremental cost-effectiveness ratios 
were calculated for the remaining strategies and weakly dominated strategies (higher incremental 
cost-effectiveness ratios than more effective strategies) were eliminated. The optimal strategies 
for men and women were identified by using a cost-effectiveness threshold value (i.e. 
willingness to pay) of $5,150; this is approximately three times Uzbekistan’s gross domestic 
product (GDP) per capita of $1,716.53.11 
 
Sensitivity Analysis 
A total of 14 one-way sensitivity analyses were conducted each for men and women to measure 
the robustness of the model-based CEA results. The model parameters adjusted for the sensitivity 
analysis included: statin cost, lab test cost, all acute and chronic events cost, utility values, statin 
compliance level, effectiveness of statins and calibration values. Model-based CEA was 
conducted for each analysis and the optimal strategies were identified by using the same cost-
effectiveness threshold value of $5,150. Details on the sensitivity analyses performed and the 
adjusted parameters can be found in Appendix A7. 
 
RESULTS  
Table 2 shows the population characteristics of the UHES study population by sex for the 
individuals for whom complete data were available (individuals living in Tashkent City). Table 
A2-3 shows the population characteristics for the full UHES population. Approximately 38.3% 
of men in the UHES Tashkent population had a moderate to high CVD risk (SCORE risk >1%) 
and 3.2% had a high CVD risk (SCORE risk >5%) while 0.4% of women in the DHS Tashkent 
population had a moderate to high CVD risk and 0% had a high CVD risk (Table 3). 
In men, the Spearman rank correlation coefficients for the laboratory-based and non-laboratory-
based scores ranged from 0.872-0.984 (Table 4). Using the non-laboratory-based score and the 
SCORE risk score for high-risk countries, 98.4% of men were equivalently characterized as 
“high” or “moderate to low” risk individuals and 93.6% of men were equivalently characterized 
as “moderate to high” or “low” risk individuals (Table 4). In women, the Spearman rank 
correlation coefficients for the laboratory and non-laboratory-based scores ranged from 0.937-
0.980 (Table 5). Figures 2,3 and 4 depict the agreement in risk characterization between SCORE 
and non-laboratory-based risk scores for men and women.  
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Table 6 shows the average-per-person costs, QALYs and incremental cost-effectiveness ratios 
calculated for each strategy. In the base-case analysis, only one SCORE strategy for men was on 
the efficient frontier (strategy had the highest cost and QALY results with an incremental cost-
effectiveness ratio of $91,798.86/QALY) and no SCORE strategies were on the efficient frontier 
for women (i.e. all laboratory-based SCORE strategies were dominated). Using a willingness to 
pay for health of $5,150, the non-laboratory-B with limited screening strategy is optimal for 
men, and no screening is optimal for women.  
Table 7 shows the optimal strategies for each parameter adjustment in the sensitivity analysis. 
For both men and women, the model-based CEA results were most sensitive to variations in all 
types of cost, drug effectiveness and statin compliance. Details on the CEA results for the 
sensitivity analysis can be found in Appendix A7.  
 
DISCUSSION  
There was high correlation between the laboratory-based and non-laboratory-based risk scores in 
both men and women in the empirical analysis of the UHES data. In men, there was also a high 
level of agreement in risk characterization when using conventional cutoffs for high- and 
moderate-CVD risk. SCORE had the highest level of agreement between the non-laboratory-
based and laboratory-based risk scores among all of the laboratory-based risk scores. These 
results suggest that the inexpensive and fast non-laboratory based CVD risk score can be an 
effective alternative to the more commonly used laboratory-based risk scores for men in 
Tashkent City, Uzbekistan.  
The base-case CEA shows that limited non-laboratory-based CVD screening is cost-effective for 
men. Specifically, it is cost-effective to use the non-laboratory based risk score to assess and then 
treat the top 1.60% of the male population who are at the highest risk for developing CVD (given 
a threshold of $5,150/QALY). The base-case CEA shows that no screening is cost-effective for 
women in Uzbekistan. When the costs of lab screening tests were set to zero in the sensitivity 
analysis, SCORE was almost always dominated (except for the SCORE-D strategy for men, 
which had the highest cost, QALY, and ICER results). This suggests that the non-laboratory risk 
score strategies are not only cost-effective because they do not include expensive lab tests, but 
that they potentially predict CVD risk better than SCORE.  
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There were several limitations in this study. First, the data was limited to individuals living in 
Tashkent City and may not be representative of the entire Uzbekistan population (as shown in 
Table 2 and Table A2-3 in the Appendix, individuals in Tashkent City have a higher prevalence 
of diabetes and smoking than the entire Uzbekistan population). In addition, due to the relatively 
young age of the female UHES population, the agreement in risk characterization between 
laboratory and non-laboratory scores was not calculated. The model population was also based 
off of this limited female dataset. In future studies, the comparative assessment findings in this 
study need to be validated in a female population. The majority of the disease progression 
values, costs and utilities were based on populations similar to Uzbekistan. There is likely to be 
some discrepancy between the true setting-specific costs and utility values for an Uzbekistani 
population and the values used in the micro-simulation model. In addition, the model has not 
been successfully validated after calibration (comparing the calibrated model’s generated age-
specific CVD mortality to WHO reported CVD mortality in Uzbekistan).  
This study has some important policy implications. A 2013 report published by the World Bank 
stated that both the government and households in Central Asia would benefit from improvement 
in CVD health care financing.12 Since Uzbekistan is a lower-middle income country in this 
region, individuals providing and paying for health care in Uzbekistan can greatly benefit from 
this inexpensive, cost-effective screening method. In 2007, AmeriCares and Soglom, a local non-
governmental organization, launched the Central Asia Cardiovascular Disease Initiative.13 As 
part of this effort, AmeriCares partnered with Merck to increase the availability of statins in 
Uzbekistan by identifying individuals who were at high risk for developing CVD and providing 
them with statins.13 Non-profits and pharmaceutical companies working in Uzbekistan can use 
the non-laboratory-based CVD risk prediction method to assess CVD risk in a more cost-
effective way.    
The results from this study validate the previous findings from studies based on South African 
and NHANES United States populations. Future studies should aim to validate these findings in 
other low- and middle-income countries to establish the exchangeability between non-laboratory 
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TABLES 
Table 1: Strategy type and proportion of the population treated with statins  
Strategy  Treatment  Threshold Population treated 
Special No treatment 0.00% 
Nonlab-A  Threshold>40% 0.80% 
Nonlab-B  Threshold>30% 1.60% 
Nonlab-C  Threshold>20% 4.30% 
Nonlab-D  Threshold>10% 19.70% 
 SCORE-A  Threshold>7.5% 0.80% 
 SCORE-B  Threshold>6.3% 1.60% 
SCORE-C  Threshold>4.6% 4.30% 
SCORE-D  Threshold>1.6% 19.70% 
 
 
Table 2: Population characteristics of individuals who met the inclusion criteria  
 
 
Males (n= 376) Females (n=476) 
  
Mean  Mean  
Age (years) 39.0 
 
36.7 
 Current smoker 52.9% 
 
3.2% 
 History of diabetes  6.9% 
 
2.9% 
 Systolic blood pressure (mmHg) 123.8 
 
112.9 
 Blood pressure treatment  3.2% 
 
1.5% 
 Total cholesterol (mg/dL) 162.2 
 
161.3 
 HDL cholesterol (mg/dL0 38.6 
 
42.6 







Table 3:  CVD risk profile of individuals who met the inclusion criteria  
 
  Males (n=376) Females (n=477) Total (n=853) 
Moderate to high risk > 1% 144 (38.3) 2 (0.4) 146 (17.1) 
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Table 4: Percent agreement in risk characterization for six laboratory-based risk scores 
compared to non-laboratory-based risk score, Males   
 
Males (n=376) 
   
Risk Score  
Percent Agreement, 
Moderate to High 
Risk > 1% 
Percent 
Agreement, High 
Risk > 5% 
Spearman 
Correlation  
Framingham CVD 10 yr (2008) 89.4% 98.4% 0.933 
Framingham CVD 10 yr (1991) 91.5% 98.4% 0.943 
Framingham CHD 10 yr (1991) 85.6% 97.9% 0.872 
Score 10 yr high risk 93.6% 98.4% 0.984 
Score 10 yr low risk 93.6% 98.4% 0.984 











Table 5: Percent agreement in risk characterization for six laboratory-based risk scores 




	   	  Risk Score  Spearman Correlation  
Framingham CVD 10 yr (2008) 0.906  
Framingham CVD 10 yr (1991) 0.914  
Framingham CHD 10 yr (1991) 0.937  
Score 10 yr high risk 0.980  
Score 10 yr low risk 0.980  




	   14	  
Table 6: Base-case cost-effectiveness results for nondominated strategies 
 
Strategy Type Threshold Costs  QALYs ICER 
Males 
    
 
No treatment  No treatment  $590.79 15.385 - 
 
Nonlab-A Threshold >40% $596.00 15.391 $842.72 
 
Nonlab-B Threshold>30% $605.75 15.396 $1,719.78 
 
Nonlab-C Threshold>20% $628.26 15.400 $5,523.37 
 
Nonlab-D Threshold>10% $679.40 15.408 $6,551.13 
 
SCORE-D Threshold>1.6% $745.81 15.409 $91,798.86 
      Females 
    
 
No treatment No treatment $306.02 18.150 - 
 
Nonlab-A Threshold>40% $312.31 18.151 $6,249.15 
 
Nonlab-C Threshold>20% $356.15 18.156 $9,876.10 
 









  Strategy  ICER  Strategy  ICER  
Base-case  Nonlab-B $1,719.78 No treatment  - 
Half Statin  Nonlab-C $4,670.24 Nonlab-A $5,048.40 
Free Statin  Nonlab-D $4,760.08 Nonlab-A $3,845.04 
Free Lab Test  Nonlab-D  $2,679.28 Nonlab-C $4,574.26 
Statin RR + 25% No treatment  - No treatment  - 
Statin RR - 25% Nonlab-D $5,022.72 Nonlab-C $5,034.12 
Statin RR + 10% Nonlab-B $4,792.57 No treatment  - 
Statin RR - 10% Nonlab-D $4,756.51 Nonlab-A $1,642.51 
All Event Costs + 25% Nonlab-C $4,864.67 Nonlab-A $4,821.13 
All Event Costs - 25% Nonlab-B $1,847.02 No treatment  - 
Utility + 25% Nonlab-B $1,729.15 No treatment  - 
Utility - 25% Nonlab-B $2,392.54 No treatment  - 
Statin Compliance = 1 Nonlab-D $4,856.42 Nonlab-B $4,328.06 
Uncalibrated Model Nonlab-C  $3,998.23 Nonlab-A $718.07 
 
  












	   16	  





















	   17	  


























	   18	  





	   	  
	   19	  
REFERENCES 
 
1. World Health Organization. Uzbekistan; 2011. 
2. World Health Organization Europe. Highlights on Health in Uzbekistan 2005; 2006. 
3. Pandya A, Weinstein MC, Gaziano TA. A Compartive Assessment of Non-Laboratory-
Based versus Commonly Used Laboratory-Based Cardiovascular Disease Risk scores in the 
NHANES III Population. PLoS ONE 2011;6. 
4. Gaziano TA, Pandya A, Steyn K, et al. Comparative assessment of absolute 
cardiovascular disease risk characterization from non-laboratory-based risk assessment in South 
African populations. BMC Medicine 2013;11:170. 
5. Analytical and Information Center Ministry of Health of the Republic of Uzbekistan, 
State Department of Statistics Ministry of Macroeconomics and Statistics, ORC Macro. 
Uzbekistan Health Examination Survey 2002. Calverton, Maryland, USA; 2004. 
6. Joep Perk et al. European Guidelines on Cardiovascular Disease Prevention in Clinical 
Practice. European Heart Journal 2012:1635-701. 
7. Central Intelligence Agency. The World Factbook - Uzbekistan; 2013. 
8. Pandya A, Weinstein MC, Salomon JA, Cutler D, Gaziano TA. Who Needs Laboratories 
and Who Needs Statins? Comparative and Cost-Effectiveness Analyses of Non-Laboratory-
Based, Laboratory-Based, and Staged Primry Cardiovascular Disease Screening Guidelines. 
Circulation: Cardiovascular Quality and Outcomes 2014;7:25. 
9. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-Effectiveness Analysis 
of Hypertension Guidelines in South Africa: Absolute Risk Versus Blood Pressure Level. 
Circulation 2005:3569-76. 
10. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a 
multidrug regimen in the developing world: a cost-e!ectiveness analysis. Lancet 2006:679-86. 
11. World Bank. Uzbekistan Data. In; 2012. 
12. Smith O, Nguyen SN. Getting better : improving health system outcomes in Europe and 
Central Asia: World Bank; 2013. Report No.: 78185. 
13. Kher U. Saving Uzbek Hearts: A Program for Best Practices in Controlling 








Table-A1: Study populations, inputs and outcomes used to create each of the six CVD risk 
scores assessed in this study1  
 






Age, sex, smoking status, 
diabetes history, systolic 
blood pressure, treatment for 
hypertension, BMI 









Age, sex, smoking status, 
diabetes history, systolic 
blood pressure, treatment for 
hypertension, total 
cholesterol, HDL cholesterol 
CVD death, CHD 










Age, sex, smoking status, 
diabetes history, systolic 
blood pressure, total 
cholesterol, HDL cholesterol 
CVD death, CHD 










Age, sex, smoking status, 
diabetes history, systolic 
blood pressure, total 
cholesterol, HDL cholesterol 









Age, sex, smoking status, 










Age, sex, smoking status, 








Age, sex, smoking status, 
diabetes history, systolic 
blood pressure, treatment for 
hypertension, total 
cholesterol, HDL cholesterol 
Fatal and non-fatal 
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Appendix-A2: Regression Used to Populate CVD Risk Factors for Simulation Model 
Population 
The male-specific regressions used for the model population were created in the following 
sequential order: 
  
1.     probability (smoking)= age + age2 
2.     BMI = age + age2 
3.     probability (diabetes) = age + BMI 
4.     Total cholesterol = age 
5.     HDL cholesterol = age + BMI 
6.     Systolic blood pressure, unadjusted = age + BMI 
7.     Probability (treatment for hypertension) = age + BMI + BMI2 + systolic blood pressure 
  
The female-specific regressions used for the model population were created in the following 
sequential order: 
 
1.     probability (smoking)= age + age2 
2.     BMI = age + age2 
3.     probability (diabetes) = age + BMI 
4.     Total cholesterol = age 
5.     HDL cholesterol = age + BMI 
6.     Systolic blood pressure, unadjusted = age + BMI 
7.     Probability (treatment for hypertension) = age + age2 + BMI + BMI2 + systolic blood 
pressure 
 
The regressions were created in this sequence based on a previously published analysis of CVD 
risk factors in the U.S.2 Table-A2-1 and Table-A2-2 show the coefficients for predictors of each 
CVD risk factor for men and women respectively. Predictors were only included if they were 
statistically significant at a p<0.10 level. For internal validity of the model-generated population, 
population characteristics of the model-generated population, an age-restricted model generated 
population and the UHES population were compared (Table-A2-3). The age-restricted 
population only includes population characteristics of men ages 59 and below and women ages 
49 and below (maximum ages in UHES population), making it easier to directly compare the 
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Table-A2-1: Regression coefficients for CVD risk factor and treatment variables, men 
  Independent Variables              
  






Smoking 3.3385 -0.1310 0.0015 -- -- -- -- -- -- 
BMI 15.0949 0.4050 -0.0037 -- -- -- -- -- -- 
Diabetes 9.4236 -0.0605 -- -- -0.1211 -- -- -- -- 
Total 
Cholesterol 142.1983 0.4992 -- -- -- -- -- -- -- 
HDL 




96.6417 0.2754 -- -- 0.5768 -- -- -- -- 
Treatment for 
Hypertension 31.3845 -0.0395 -- -- -1.2543 0.0201 -- -- -0.0595 
 
 
Table-A2-2: Regression coefficients for CVD risk factor and treatment variables, women  
      Independent Variables              
  






Smoking 4.5475 -0.0011 -- -- -- -- -- -- -- 
BMI 18.3512 0.1786 -- -- -- -- -- -- -- 
Diabetes 11.2724 -0.1643 -- -- -- -- -- -- -- 
Total 
Cholesterol 230.0178 -5.1772 0.0867 -- -- -- -- -- -- 
HDL 




95.2372 -0.8082 0.0186 -0.2887 1.0469 -0.0067 -- -- -- 
Treatment for 
Hypertension 11.6588 -0.0720 -- -- -0.0252 -- -- -- -0.0462 
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Age (years) 41.3 38.8 37.6 
Current smoker 34.1% 35.2% 34.5% 
History of Diabetes 2.8% 2.2% 2.3% 
Systolic blood pressure 
(mmHg) 122.3 121.5 121.3 
Blood pressure treatment  3.8% 3.2% 3.0% 
Total cholesterol (mg/dL)** 163.1 162.3 161.6 
HDL Cholesterol (mg/DL)** 39.0 38.6 38.6 
Body-mass index (kg/m2) 24.9 24.9 24.8 
Framingham CVD 10 yr 
(2008) 8.251 6.569 7.634 
    
    









Age (years) 42.0 35.5 35.6 
Current smoker 1.0% 1.0% 1.1% 
History of Diabetes 6.3% 0.7% 0.8% 
Systolic blood pressure 
(mmHg) 119.5 113.0 112.6 
Blood pressure treatment  15.3% 5.6% 5.7% 
Total cholesterol (mg/dL)** 179.3 160.5 161.5 
HDL Cholesterol (mg/DL)** 43.3 43.1 42.6 
Body-mass index (kg/m2) 25.7 24.7 24.7 
Framingham CVD 10 yr 
(2008) 6.266 1.796 1.938 
 
* For comparison purposes ,the restricted model only includes men from the model population 
that are between the ages of 25-59 and women from the model population that are between ages 
of 25-49 (same age range as the UHES population) 
 
**The UHES means for total cholesterol and HDL cholesterol were based only on individuals 
living in Tashkent City, Uzbekistan (n=853) because cholesterol data was not available for other 
regions in Uzbekistan.   
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Appendix-A3: CVD micro-simulation model 
The overall model structure is depicted in Figure 1 in the main text, and the possible transitions 
are shown in greater detail in Figure-A3. 3-5 
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Appendix-A4: Disease Progression  
Acute (i.e. within the first year of experiencing the event) and chronic (i.e. any year after the first 
year that the event was experienced) post-event mortality were calculated separately. The model 
tracked all CHD and stroke related events through each individual’s lifetime, calculating the 
associated mortality, costs and quality-of-life for each individual.  
 
 
Table-A4: Disease progression inputs used in the CVD micro-simulation model 
 
Parameter Value Source 
From Disease Free State 
  CVA Event table Wolf, 19916 
CHD Event table Anderson, 19917 
  % Cardiac Arrest table Gaziano, 20053 
  % MI male 0.35 Ratkov, 20088 
  % MI female 0.2 Ratkov, 20088 
  % Angina formula 100% - % Cardiac arrest - %MI 
From Cardiac Arrest State 
  Acute 1-Year Death (under 71) 0.954 Nichol, 20089 
Non-CVD Death 0.04 Assumption:  same as MI 
CVA Event table Wolf, 19916 
  % Acute CVA Death Post 
Arrest 0.116 Assumption:  same as MI 
MI Event 0.064 Assumption:  same as MI 
From Myocardial Infarction State 
 Acute 30-Day Death table Lee, 201010; Luksiene, 201111 
Acute CABG 0.025 Gaziano, 20053 
Acute PTCA 0.025 Gaziano, 20053 
  % Procedure Death 0.009 Law, 200212; Luksiene, 201111 
Acute 2nd MI no PTCA 0.060 Capewell, 200613 
Acute 2nd MI after PTCA 0.052 BARI, 199614 
  % 2nd MI Death Table Lee, 201010 
Non-CVD Death 0.040 Law 200212; Kokutsov, 198915 
  >1 previous MI 0.100 Law, 200212 
CVA Event Table Wolf, 19916 
  % Acute CVA Death Post MI 0.116 Witt, 200516  
Repeat MI 0.064 Jokhadar, 200417 
From MI and CABG State  
  Acute Post-CABG Death 0.027 Luksiene, 2011; Law, 200212 
Acute 2nd MI 0.051 BARI, 199614 
  % 2nd MI Death Table Lee, 201010 
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Non-CVD Death 0.040 Assumption:  same as MI 
  >1 previous MI 0.100 Assumption:  same as MI 
CVA Event table Wolf, 19916 
  % Acute CVA Post 
MI_CABG 0.116 Assumption:  same as MI 
Repeat MI 0.039 Yusef, 199418 
From Angina State 
  Acute Death 0.045 Capewell, 200613 
Acute Cardiac Arrest 0.006 Hsia, 200819 
Acute MI 0.035 Hemingway, 200320 
Acute CABG 0.050 Gaziano, 20053 
Acute PTCA 0.050 Gaziano, 20053 
  % Procedure Death 0.009 Dorros, 198421 
Non-CVD Death 0.030 Law, 200212 
CVA Event table Wolf, 19916 
  % Acute CVA Death Post 
Angina 0.116 Assumption:  same as MI 
MI Event 0.035 Hemingway, 200320 
  % acute MI Death table 
Assumption:  same as MI, Lee 
201010  
From Angina and CABG State  
  Acute Post-CABG Death 0.027 Peterson, 200422 
Non-CVD Death 0.018  Yusef, 199418 
CVA Event table Wolf, 19916 
  % Acute CVA Post Ang 
CABG 0.116 Assumption:  same as MI 
MI Event 0.021 Yusef, 1994 
From Cardiovascular Accident/Stroke State 
 Acute CVD Death 0.140 Davídkovová, 201323 
Non-CVD Death 0.050 Law, 200212 
  >1 previous MI 0.100 Law, 200212 
Repeat CVA Event 0.040 Hardie, 200424 
MI Event 0.022 Touze, 200525 
 
 
Appendix-A5: Costs and Utilities  
Base-case event-based cost values were based on a recent report on global chronic condition 
costs by the World Economic Forum and the Harvard School of Public Health. The analysis in 
this report used values from WHO CHOICE and expert opinion. Similar to post-event mortality, 
costs for acute and chronic events were estimated separately. Base-case statin costs were 
estimated using Management of Science and Health’s International Drug Price Indicator Guide. 
Table-A5 describes the various cost inputs used for the base-case model.  
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Base-case quality-of-life (i.e. utility) were based off Salomon’s updated global disability-
adjusted life-year (DALY) weights analysis. Adjusted QALYs were calculated by multiplying 
the time spent in each state by the associated event-specific utility value. Table-A5 describes the 
utility values used for the base-case model.  
 
Table-A5: Cost, utility, and treatment inputs used in the CVD micro-simulation model 
 
Utility Values  
  Parameter  Value Source  
For Chronic Disease States  
  Disease Free 1.000 Assumption 
Chronic RCA 0.944 Assumption (same as MI) 
Chronic MI 0.944 Salomon, 201326 
Chronic MI_CABG 0.944 Assumption (same as MI) 
Chronic Angina 0.934 Salomon, 201326 
Chronic Angina_CABG 0.934 Assumption (same as angina) 
Chronic CVA 0.924 Salomon, 201326 
Taking statin utility -0.001 
Assumption; Greving, 201127; 
Pignone, 200628 
For Acute (i.e. first year in) Disease States 
 Acute RCA 0.942 Assumption (same as MI) 
Acute MI 0.942 Salomon, 201326 
Acute MI_CABG 0.942 Assumption (same as MI) 
Acute Angina 0.934 Salomon, 201326 
Acute Angina_CABG 0.934 Assumption (same as angina) 
Acute CVA 0.924 Salomon, 201326 
Acute Disutilities for Procedures and Repeat 
Events 
 Repeat MI -0.056 Salomon, 201326 
Repeat CVA -0.076 Salomon, 201326 
CABG procedure 0.000 Assumption 
PTCA procedure 0.000 Assumption 
Minor statin adverse event -0.005 Lee, 201010 
Major statin adverse event -0.038 Lee, 201010 
   Cost Values  
  Parameter  Value Source  
For Chronic Disease States 
  Chronic RCA $67.73 Assumption:  same as MI 
Chronic MI $67.73 NCD Costing Report 201129 
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Chronic MI_CABG $67.73 Assumption:  same as MI 
Chronic Angina $67.73 Assumption:  same as MI 
Chronic Angina_CABG $67.73 Assumption:  same as MI 
Chronic CVA $65.00 NCD Costing Report 201129 
For Acute (i.e., first year in) Disease States 
 Acute RCA $2,261.00 NCD Costing Report 201129 
Acute MI $2,261.00 NCD Costing Report 201129 
Acute Angina $2,261.00 NCD Costing Report 201129 
Acute CVA $2,364.00 NCD Costing Report 201129 
Acute Costs for Procedures and Repeat Events 
 Repeat MI $2,261.00 NCD Costing Report 201129 
Repeat CVA $2,364.00 NCD Costing Report 201129 
CABG procedure $3,368.19 Perikhanyan, 201130 
PTCA procedure $4,444.00 Perikhanyan, 201130 
Screening Costs 
  Non-lab test (GP visit in Stage 
1) $8.75 NCD Costing Report 201129 
Lab test $10.00 NCD Costing Report 201129 
# extra GP visits during Stage 2 1 Assumption 
# lab tests/year after treatment 1 Lazar, 201131 




Intl Drug Price Guide, Management 
Science for Health, 201232 
Diabetes Cost  
	    Annual Cost of Diabetes  $43.06 Zhang, 201034 
   Drug effectiveness (RR) 
  Parameter  Value Source  
CHD risk 
  Statin 0.770 Lee, 201010 
Anti-hypertensive 1.000 Law, 200212 
CVA risk  
  Statin 0.830 Lee, 201010 
Anti-hypertensive 1.000 Law, 200212 
   Drug adverse reaction rate/initiation/compliance 
 Parameter  Value Source  
Statin Adverse Events  
  Minor event (probability) 0.175 Lee 201010 
Major event (probability) 0.0001 Lee 201010 
 Probability die (conditional on  
major) 0.090 Lee 201010 
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Drug compliance  
  Statin compliance 1st year 0.667 Greiving, 201127; Avorn, 199833 
Statin compliance 2nd year 0.530 Greiving, 201127; Avorn, 199833 
Statin compliance 3rd year and 
beyond 0.500 Greiving 201127, Avorn 199833 





Appendix A6: Calibration 
In order to assess the validity of the model projections for an Uzbekistani population, model-
generated age-adjusted MI and CVA incidence was compared to WHO age-adjusted MI and 
CVA incidence for Uzbekistan.  The CHD risk function parameters were not calibrated for either 
model. For men, the intercept term (“Theta 0”) was changed from .9145 to .9715 and the stroke 
risk function’s intercept term was adjusted from 5.677 to 5.75. For women, the intercept term 
(“Theta 0”) was changed from .9145 to .72 and the intercept term for the stroke risk function was 
adjusted from 7.5766 to 6.74. Table-A6 shows the overall age-adjusted MI and CVA incidence 
for the uncalibrated and calibrated models, and the target age-adjusted MI and CVA incidence.  
 
Table-A6: Age-adjusted MI and CVA incidence for males and females  
 
Males  
     Uncalibrated Model Calibrated Model Target  
MI 1.926 0.876 0.880 
CVA 0.944 2.111 2.110 
    Females 
     Uncalibrated Model Calibrated Model Target  
MI 1.926 0.876 0.880 
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Appendix-A7: Sensitivity Analysis  
A total of 14 sensitivity analyses were performed for both men and women. Table 7 in the main 
text indicates the optimal strategy for each analysis given a willingness to pay threshold of 
$5,150. Tables A7-2 and A7-16 show the CEA results when the cost of statins is decreased by 
50% for men and women respectively.  Tables A7-3 and A7-17 show the CEA results when 
statins are free for men and women respectively. The CEA results when the lab test is free for 
men and women are shown in Tables A7-4 and A7-18 respectively. This tests whether the CEA 
results for the base-case are being driven by lab costs or by the non-laboratory prediction 
method’s ability to select better patients.   
The effectiveness of statins (defined as the relative risk for developing CHD and CVA) was also 
examined in Tables A7-5, A7-6, A7-7 & A7-8 (for men) and Tables A7-19, A7-20, A7-21 and 
A7-22 (for women).  Specifically, the RR was adjusted +/- 25% and +/- 10% for both men and 
women. The maximum RR value was capped at 1 (since RR values greater than 1 would indicate 
that statins increase the risk of developing CHD and CVA).  
Tables A7-9, A7-10, A7-23 and A7-24 show the CEA results when all acute and chronic event 
costs are increased/decreased together by 25% for men and women. In these analyses, only the 
event costs were adjusted – costs for statins and lab tests were not adjusted. Tables A7-11, A7-
12, A7-25 and A7-25 show the CEA results when all utility values were adjusted +/- 25% for 
men and women. The CEA results when statin compliance for all years is equal to one are shown 
in Tables A7-13 and A7-27. Tables A7-14 and A7-28 show the CEA results based off of the 
uncalibrated model.   
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Table-A7-1: Base Case CEA, Men 
 
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment  $590.79  15.385 - 
Nonlab-A Threshold>40% $596.00  15.391 - 
Nonlab-B Threshold>30% $605.75  15.396 - 
Nonlab-C Threshold>20% $628.26  15.400 - 
Nonlab-D Threshold>10% $679.40  15.408 - 
SCORE-A Threshold>7.5% $690.66  15.395 Strongly Dominated 
SCORE-B Threshold>6.3% $696.43  15.394 Strongly Dominated 
SCORE-C Threshold>4.6% $705.17  15.396 Strongly Dominated 
SCORE-D Threshold>1.6% $745.81  15.409 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER  
No treatment  No treatment  $590.79  15.385 - 
Nonlab-A Threshold>40% $596.00  15.391 $842.72  
Nonlab-B Threshold>30% $605.75  15.396 $1,719.78  
Nonlab-C Threshold>20% $628.26  15.400 $5,523.37  
Nonlab-D Threshold>10% $679.40  15.408 $6,551.13  
SCORE-D Threshold>1.6% $745.81  15.409 $91,798.86  
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Table-A7-2: Statin cost decreased by 50%, Men 
 
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $586.18  15.385 - 
Nonlab-A Threshold>40% $590.42  15.391 - 
Nonlab-B Threshold>30% $598.83  15.396 - 
Nonlab-C Threshold>20% $617.86  15.400 - 
Nonlab-D Threshold>10% $662.01  15.408 - 
SCORE-A Threshold>7.5% $682.65  15.395 Strongly Dominated 
SCORE-B Threshold>6.3% $687.37  15.394 Strongly Dominated 
SCORE-C Threshold>4.6% $694.26  15.396 Strongly Dominated 
SCORE-D Threshold>1.6% $727.64  15.409 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $586.18  15.385 - 
Nonlab-A Threshold>40% $590.42  15.391 $685.53  
Nonlab-B Threshold>30% $598.83  15.396 $1,484.11  
Nonlab-C Threshold>20% $617.86  15.400 $4,670.24  
Nonlab-D Threshold>10% $662.01  15.408 $5,655.60  
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Table-A7-3: Free statin, Men  
 
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $581.56  15.385 - 
Nonlab-A Threshold>40% $584.83  15.391 - 
Nonlab-B Threshold>30% $591.91  15.396 - 
Nonlab-C Threshold>20% $607.46  15.400 - 
Nonlab-D Threshold>10% $644.63  15.408 - 
SCORE-A Threshold>7.5% $674.64  15.395 Strongly Dominated 
SCORE-B Threshold>6.3% $678.30  15.394 Strongly Dominated 
SCORE-C Threshold>4.6% $683.34  15.396 Strongly Dominated 
SCORE-D Threshold>1.6% $709.47  15.409 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $581.56  15.385 - 
Nonlab-A Threshold>40% $584.83  15.391 $528.34  
Nonlab-B Threshold>30% $591.91  15.396 $1,248.44  
Nonlab-C Threshold>20% $607.46  15.400 $3,817.14  
Nonlab-D Threshold>10% $644.63  15.408 $4,760.08  
SCORE-D Threshold>1.6% $709.47  15.409 $89,634.58  
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Table-A7-4: Free lab test, Men 
 
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $591.84  15.391 - 
Nonlab-B Threshold>30% $595.97  15.396 - 
Nonlab-C Threshold>20% $603.48  15.400 - 
Nonlab-D Threshold>10% $624.40  15.408 - 
SCORE-A Threshold>7.5% $633.94  15.395 Strongly Dominated 
SCORE-B Threshold>6.3% $635.99  15.394 Strongly Dominated 
SCORE-C Threshold>4.6% $638.56  15.396 Strongly Dominated 
SCORE-D Threshold>1.6% $655.43  15.409 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $591.84  15.391 $170.20  
Nonlab-B Threshold>30% $595.97  15.396 $728.28  
Nonlab-C Threshold>20% $603.48  15.400 $1,844.01  
Nonlab-D Threshold>10% $624.40  15.408 $2,679.28  
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Table-A7-5: Statin RR for CHD and CVA increased by 25%, Men 
  
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $599.89  15.385 - 
Nonlab-B Threshold>30% $612.01  15.385 Strongly Dominated 
Nonlab-C Threshold>20% $643.54  15.386 - 
SCORE-A Threshold>7.5% $701.14  15.386 Strongly Dominated 
Nonlab-D Threshold>10% $705.87  15.389 - 
SCORE-B Threshold>6.3% $708.95  15.385 Strongly Dominated 
SCORE-C Threshold>4.6% $722.12  15.385 Strongly Dominated 
SCORE-D Threshold>1.6% $773.79  15.387 Strongly Dominated 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $599.89  15.385 $11,863.72  
Nonlab-C Threshold>20% $643.54  15.386 $37,817.17  
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Table-A7-6: Statin RR for CHD and CVA decreased by 25%, Men   
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $591.19  15.392 - 
Nonlab-B Threshold>30% $595.14  15.398 - 
Nonlab-C Threshold>20% $609.64  15.409 - 
Nonlab-D Threshold>10% $649.03  15.417 - 
SCORE-A Threshold>7.5% $677.02  15.397 Strongly Dominated 
SCORE-B Threshold>6.3% $680.69  15.397 Strongly Dominated 
SCORE-C Threshold>4.6% $685.84  15.402 Strongly Dominated 
SCORE-D Threshold>1.6% $715.49  15.420 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $591.19  15.392 $54.93  
Nonlab-B Threshold>30% $595.14  15.398 $634.55  
Nonlab-C Threshold>20% $609.64  15.409 $1,274.97  
Nonlab-D Threshold>10% $649.03  15.417 $5,022.72  
SCORE-D Threshold>1.6% $715.49  15.420 $25,301.22  
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Table-A7-7: Statin RR for CHD and CVA increased by 10%, Men 
All Strategies          
 Strategy  Threshold Costs QALYs Dominance 
 No treatment  No treatment $590.79  15.385 - 
 Nonlab-A Threshold>40% $597.30  15.389 - 
 Nonlab-B Threshold>30% $607.55  15.391 - 
 Nonlab-C Threshold>20% $634.51  15.394 - 
 Nonlab-D Threshold>10% $689.69  15.402 - 
 SCORE-A Threshold>7.5% $695.20  15.390 Strongly Dominated 
 SCORE-B Threshold>6.3% $700.97  15.389 Strongly Dominated 
 SCORE-C Threshold>4.6% $711.19  15.392 Strongly Dominated 
 SCORE-D Threshold>1.6% $756.23  15.402 - 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance 
No treatment  No treatment $590.79  15.385 - - 
Nonlab-A Threshold>40% $597.30  15.389 $1,627.32  - 
Nonlab-B Threshold>30% $607.55  15.391 $4,792.57  - 
Nonlab-C Threshold>20% $634.51  15.394 $8,036.40  Weakly Dominated 
Nonlab-D Threshold>10% $689.69  15.402 $7,310.67  - 
SCORE-D Threshold>1.6% $756.23  15.402 $99,553.88  - 
      Efficient Frontier (Nondominated Strategies)      
 Strategy  Threshold Costs QALYs ICER 
 No treatment  No treatment $590.79  15.385 - 
 Nonlab-A Threshold>40% $597.30  15.389 $1,627.32  
 Nonlab-B Threshold>30% $607.55  15.391 $4,792.57  
 Nonlab-D Threshold>10% $689.69  15.402 $7,534.02  
 SCORE-D Threshold>1.6% $756.23  15.402 $99,553.88  
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Table-A7-8: Statin RR for CHD and CVA decreased by 10%, Men  
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $594.25  15.392 - 
Nonlab-B Threshold>30% $602.13  15.399 - 
Nonlab-C Threshold>20% $620.79  15.404 - 
Nonlab-D Threshold>10% $668.09  15.414 - 
SCORE-A Threshold>7.5% $685.04  15.397 Strongly Dominated 
SCORE-B Threshold>6.3% $690.38  15.397 Strongly Dominated 
SCORE-C Threshold>4.6% $698.37  15.402 Strongly Dominated 
SCORE-D Threshold>1.6% $734.88  15.414 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $594.25  15.392 $453.51  
Nonlab-B Threshold>30% $602.13  15.399 $1,188.29  
Nonlab-C Threshold>20% $620.79  15.404 $3,772.92  
Nonlab-D Threshold>10% $668.09  15.414 $4,756.51  
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Table-A7-9: All event costs (acute and chronic) increased by 25%, Men 
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $727.56  15.385 - 
Nonlab-A Threshold>40% $731.69  15.391 - 
Nonlab-B Threshold>30% $740.70  15.396 - 
Nonlab-C Threshold>20% $760.53  15.400 - 
Nonlab-D Threshold>10% $808.25  15.408 - 
SCORE-A Threshold>7.5% $824.35  15.395 Strongly Dominated 
SCORE-B Threshold>6.3% $829.44  15.394 Strongly Dominated 
SCORE-C Threshold>4.6% $836.90  15.396 Strongly Dominated 
SCORE-D Threshold>1.6% $874.45  15.409 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $727.56  15.385 - 
Nonlab-A Threshold>40% $731.69  15.391 $667.59  
Nonlab-B Threshold>30% $740.70  15.396 $1,590.61  
Nonlab-C Threshold>20% $760.53  15.400 $4,864.67  
Nonlab-D Threshold>10% $808.25  15.408 $6,112.13  
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Table-A7-10: All event costs (acute and chronic) decreased by 25%, Men  
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $455.06  15.385 - 
Nonlab-A Threshold>40% $461.35  15.391 - 
Nonlab-B Threshold>30% $471.81  15.396 - 
Nonlab-C Threshold>20% $496.99  15.400 - 
Nonlab-D Threshold>10% $551.55  15.408 - 
SCORE-A Threshold>7.5% $557.99  15.395 Strongly Dominated 
SCORE-B Threshold>6.3% $564.43  15.394 Strongly Dominated 
SCORE-C Threshold>4.6% $574.43  15.396 Strongly Dominated 
SCORE-D Threshold>1.6% $618.15  15.409 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $455.06  15.385 - 
Nonlab-A Threshold>40% $461.35  15.391 $1,016.46  
Nonlab-B Threshold>30% $471.81  15.396 $1,847.02  
Nonlab-C Threshold>20% $496.99  15.400 $6,176.70  
Nonlab-D Threshold>10% $551.55  15.408 $6,988.37  
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Table-A7-11: All utility values increased by 25%, Men  
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $590.79  15.459 - 
Nonlab-A Threshold>40% $596.00  15.464 - 
Nonlab-B Threshold>30% $605.75  15.470 - 
Nonlab-C Threshold>20% $628.26  15.473 - 
Nonlab-D Threshold>10% $679.40  15.479 - 
SCORE-A Threshold>7.5% $690.66  15.469 Strongly Dominated 
SCORE-B Threshold>6.3% $696.43  15.467 Strongly Dominated 
SCORE-C Threshold>4.6% $705.17  15.468 Strongly Dominated 
SCORE-D Threshold>1.6% $745.81  15.480 Strongly Dominated 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $590.79  15.459 - 
Nonlab-A Threshold>40% $596.00  15.464 $890.02  
Nonlab-B Threshold>30% $605.75  15.470 $1,729.15  
Nonlab-C Threshold>20% $628.26  15.473 $8,006.54  
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Table-A7-12: All utility values decreased by 25%, Men  
All Strategies          
Strategy  Threshold Costs QALYs Dominance 
No treatment  No treatment $590.79  11.537 - 
Nonlab-A Threshold>40% $596.00  11.542 - 
Nonlab-B Threshold>30% $605.75  11.546 - 
Nonlab-C Threshold>20% $628.26  11.549 - 
Nonlab-D Threshold>10% $679.40  11.554 - 
SCORE-A Threshold>7.5% $690.66  11.545 Strongly Dominated 
SCORE-B Threshold>6.3% $696.43  11.544 Strongly Dominated 
SCORE-C Threshold>4.6% $705.17  11.545 Strongly Dominated 
SCORE-D Threshold>1.6% $745.81  11.554 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
No treatment  No treatment $590.79  11.537 - 
Nonlab-A Threshold>40% $596.00  11.542 $1,154.57  
Nonlab-B Threshold>30% $605.75  11.546 $2,392.54  
Nonlab-C Threshold>20% $628.26  11.549 $8,610.17  
Nonlab-D Threshold>10% $679.40  11.554 $10,232.28  
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Table-A7-13: Statin compliance in all years equal to 1, Men  
All Strategies          
Strategy  Threshold Costs  QALYs Dominance 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $592.67  15.392 - 
Nonlab-B Threshold>30% $600.10  15.399 - 
Nonlab-C Threshold>20% $620.20  15.412 - 
Nonlab-D Threshold>10% $669.89  15.422 - 
SCORE-A Threshold>7.5% $683.38  15.398 Strongly Dominated 
SCORE-B Threshold>6.3% $688.80  15.398 Strongly Dominated 
SCORE-C Threshold>4.6% $696.06  15.404 Strongly Dominated 
SCORE-D Threshold>1.6% $737.44  15.423 - 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs  QALYs ICER 
No treatment  No treatment $590.79  15.385 - 
Nonlab-A Threshold>40% $592.67  15.392 $259.14  
Nonlab-B Threshold>30% $600.10  15.399 $978.54  
Nonlab-C Threshold>20% $620.20  15.412 $1,656.80  
Nonlab-D Threshold>10% $669.89  15.422 $4,856.42  
SCORE-D Threshold>1.6% $737.44  15.423 $49,208.66  
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Table-A7-14: Uncalibrated Model, Men  
 
All Strategies          
 Strategy  Threshold Costs QALYs Dominance 
 No treatment  No treatment $516.92  15.447 - 
 Nonlab-A Threshold>40% $519.27  15.446 Strongly Dominated 
 Nonlab-B Threshold>30% $528.30  15.448 - 
 Nonlab-C Threshold>20% $553.04  15.456 - 
 Nonlab-D Threshold>10% $608.17  15.467 - 
 SCORE-A Threshold>7.5% $614.96  15.450 Strongly Dominated 
 SCORE-B Threshold>6.3% $621.56  15.450 Strongly Dominated 
 SCORE-C Threshold>4.6% $630.92  15.452 Strongly Dominated 
 SCORE-D Threshold>1.6% $674.62  15.467 - 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance 
No treatment  No treatment $516.92  15.447 - - 
Nonlab-B Threshold>30% $528.30  15.448 $10,523.73  
Weakly 
Dominated 
Nonlab-C Threshold>20% $553.04  15.456 $3,110.62  - 
Nonlab-D Threshold>10% $608.17  15.467 $5,196.99  - 
SCORE-D Threshold>1.6% $674.62  15.467 $396,222.22  - 
      Efficient Frontier (Nondominated Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 No treatment  No treatment $516.92  15.447 - 
 Nonlab-C Threshold>20% $553.04  15.456 $3,998.23  
 Nonlab-D Threshold>10% $608.17  15.467 $5,196.99  
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Table-A7-15: Base Case CEA, Women 
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $306.02  18.150 - 
 Nonlab-A Threshold>40% $312.31  18.151 - 
 Nonlab-B Threshold>30% $325.52  18.152 - 
 Nonlab-C Threshold>20% $356.15  18.156 - 
 Nonlab-D Threshold>10% $416.05  18.159 - 
 SCORE-A Threshold>7.5% $422.50  18.154 Strongly Dominated 
 SCORE-B Threshold>6.3% $427.84  18.154 Strongly Dominated 
 SCORE-C Threshold>4.6% $439.91  18.156 Strongly Dominated 
 SCORE-D Threshold>1.6% $473.14  18.158 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $306.02  18.150 - - 
Nonlab-A Threshold>40% $312.31  18.151 $6,249.17  - 
Nonlab-B Threshold>30% $325.52  18.152 $34,331.97  Weakly dominated 
Nonlab-C Threshold>20% $356.15  18.156 $7,554.52  - 
Nonlab-D Threshold>10% $416.05  18.159 $16,192.49  - 
      Efficient Frontier (Nondominated 
Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $306.02  18.150 - 
 Nonlab-A Threshold>40% $312.31  18.151 $6,249.17  
 Nonlab-C Threshold>20% $356.15  18.156 $9,876.11  
 Nonlab-D Threshold>10% $416.05  18.159 $16,192.49  
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Table-A7-16: Statin cost decreased by 50%, Women  
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $303.86  18.150 - 
 Nonlab-A Threshold>40% $308.94  18.151 - 
 Nonlab-B Threshold>30% $320.54  18.152 - 
 Nonlab-C Threshold>20% $347.28  18.156 - 
 Nonlab-D Threshold>10% $400.29  18.159 - 
 SCORE-A Threshold>7.5% $417.85  18.154 Strongly Dominated 
 SCORE-B Threshold>6.3% $422.41  18.154 Strongly Dominated 
 SCORE-C Threshold>4.6% $432.80  18.156 Strongly Dominated 
 SCORE-D Threshold>1.6% $460.65  18.158 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $303.86  18.150 - - 
Nonlab-A Threshold>40% $308.94  18.151 $5,048.40  - 
Nonlab-B Threshold>30% $320.54  18.152 $30,138.38  Weakly Dominated 
Nonlab-C Threshold>20% $347.28  18.156 $6,594.69  - 
Nonlab-D Threshold>10% $400.29  18.159 $14,332.57  - 
      Efficient Frontier (Nondominated 
Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $303.86  18.150 - 
 Nonlab-A Threshold>40% $308.94  18.151 $5,048.40  
 Nonlab-C Threshold>20% $347.28  18.156 $8,635.88  
 Nonlab-D Threshold>10% $400.29  18.159 $14,332.57  
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Table-A7-17: Free statin, Women  
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $301.69  18.150 - 
 Nonlab-A Threshold>40% $305.56  18.151 - 
 Nonlab-B Threshold>30% $315.54  18.152 - 
 Nonlab-C Threshold>20% $338.38  18.156 - 
 Nonlab-D Threshold>10% $384.50  18.159 - 
 SCORE-A Threshold>7.5% $413.20  18.154 Strongly Dominated 
 SCORE-B Threshold>6.3% $416.97  18.154 Strongly Dominated 
 SCORE-C Threshold>4.6% $425.67  18.156 Strongly Dominated 
 SCORE-D Threshold>1.6% $448.13  18.158 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $301.69  18.150 - - 
Nonlab-A Threshold>40% $305.56  18.151 $3,845.04  - 
Nonlab-B Threshold>30% $315.54  18.152 $25,935.11  Weakly Dominated 
Nonlab-C Threshold>20% $338.38  18.156 $5,632.79  - 
Nonlab-D Threshold>10% $384.50  18.159 $12,468.58  - 
      Efficient Frontier (Nondominated 
Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $301.69  18.150 - 
 Nonlab-A Threshold>40% $305.56  18.151 $3,845.04  
 Nonlab-C Threshold>20% $338.38  18.156 $7,392.96  
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Table-A7-18: Free lab test, Women  
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $306.02  18.150 - 
 Nonlab-A Threshold>40% $307.12  18.151 - 
 Nonlab-B Threshold>30% $313.45  18.152 - 
 Nonlab-C Threshold>20% $327.43  18.156 - 
 Nonlab-D Threshold>10% $357.85  18.159 - 
 SCORE-A Threshold>7.5% $358.73  18.154 Strongly Dominated 
 SCORE-B Threshold>6.3% $360.97  18.154 Strongly Dominated 
 SCORE-C Threshold>4.6% $366.77  18.156 Strongly Dominated 
 SCORE-D Threshold>1.6% $383.56  18.158 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $306.02  18.150 - - 
Nonlab-A Threshold>40% $307.12  18.151 $1,097.01  - 
Nonlab-B Threshold>30% $313.45  18.152 $16,437.18  Weakly Dominated 
Nonlab-C Threshold>20% $327.43  18.156 $3,448.14  - 
Nonlab-D Threshold>10% $357.85  18.159 $8,224.06  - 
      Efficient Frontier (Nondominated Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $306.02  18.150 - 
 Nonlab-A Threshold>40% $307.12  18.151 $1,097.01  
 Nonlab-C Threshold>20% $327.43  18.156 $4,574.26  
 Nonlab-D Threshold>10% $357.85  18.159 $8,224.06  
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Table-A7-19: Statin RR for CHD and CVA increased by 25%, Women  
All Strategies          
Strategy  Threshold Costs QALYs Dominance  
Special No treatment $306.02  18.150 - 
Nonlab-A Threshold>40% $316.74  18.149 Strongly Dominated 
Nonlab-B Threshold>30% $333.01  18.148 Strongly Dominated 
Nonlab-C Threshold>20% $369.74  18.147 Strongly Dominated 
SCORE-A Threshold>7.5% $429.12  18.148 Strongly Dominated 
Nonlab-D Threshold>10% $431.01  18.148 Strongly Dominated 
SCORE-B Threshold>6.3% $436.47  18.148 Strongly Dominated 
SCORE-C Threshold>4.6% $451.13  18.147 Strongly Dominated 
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Table-A7-17: Statin RR for CHD and CVA decreased by 25%, Women  
All Strategies          
Strategy  Threshold Costs QALYs Dominance  
Special No treatment $306.02  18.150 - 
Nonlab-A Threshold>40% $309.01  18.153 - 
Nonlab-B Threshold>30% $317.61  18.159 - 
Nonlab-C Threshold>20% $342.32  18.163 - 
Nonlab-D Threshold>10% $399.20  18.171 - 
SCORE-A Threshold>7.5% $415.99  18.160 Strongly Dominated 
SCORE-B Threshold>6.3% $420.27  18.160 Strongly Dominated 
SCORE-C Threshold>4.6% $430.07  18.162 Strongly Dominated 
SCORE-D Threshold>1.6% $457.13  18.170 Strongly Dominated 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
Special No treatment $306.02  18.150 - 
Nonlab-A Threshold>40% $309.01  18.153 $1,162.74  
Nonlab-B Threshold>30% $317.61  18.159 $1,489.04  
Nonlab-C Threshold>20% $342.32  18.163 $5,034.12  
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Table-A7-21: Statin RR for CHD and CVA Increased by 10%, Women  
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $306.02  18.150 - 
 Nonlab-A Threshold>40% $316.34  18.150 - 
 Nonlab-B Threshold>30% $329.84  18.150 Strongly Dominated 
 Nonlab-C Threshold>20% $363.07  18.150 Strongly Dominated 
 Nonlab-D Threshold>10% $423.24  18.153 - 
 SCORE-A Threshold>7.5% $426.35  18.150 Strongly Dominated 
 SCORE-B Threshold>6.3% $432.90  18.150 Strongly Dominated 
 SCORE-C Threshold>4.6% $446.36  18.152 Strongly Dominated 
 SCORE-D Threshold>1.6% $480.23  18.152 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $306.02  18.150 - - 
Nonlab-A Threshold>40% $316.34  18.150 $81,252.01  Weakly Dominated 
Nonlab-D Threshold>10% $423.24  18.153 $40,708.92  - 
      Efficient Frontier (Nondominated 
Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $306.02  18.150 - 
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Table-A7-22: Statin RR for CHD and CVA decreased by 10%, Women  
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $306.02  18.150 - 
 Nonlab-A Threshold>40% $311.13  18.153 - 
 Nonlab-B Threshold>30% $322.88  18.154 - 
 Nonlab-C Threshold>20% $350.63  18.159 - 
 Nonlab-D Threshold>10% $408.53  18.165 - 
 SCORE-A Threshold>7.5% $419.89  18.155 Strongly Dominated 
 SCORE-B Threshold>6.3% $425.17  18.156 Strongly Dominated 
 SCORE-C Threshold>4.6% $436.68  18.159 Strongly Dominated 
 SCORE-D Threshold>1.6% $466.08  18.164 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $306.02  18.150 - - 
Nonlab-A Threshold>40% $311.13  18.153 $1,642.51  - 
Nonlab-B Threshold>30% $322.88  18.154 $10,574.19  Weakly Dominated 
Nonlab-C Threshold>20% $350.63  18.159 $5,502.23  - 
Nonlab-D Threshold>10% $408.53  18.165 $10,315.70  - 
      Efficient Frontier (Nondominated Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $306.02  18.150 - 
 Nonlab-A Threshold>40% $311.13  18.153 $1,642.51  
 Nonlab-C Threshold>20% $350.63  18.159 $6,417.64  
 Nonlab-D Threshold>10% $408.53  18.165 $10,315.70  
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Table-A7-23: All event costs (acute and chronic) increased by 25%, Women 
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $369.70  18.150 - 
 Nonlab-A Threshold>40% $374.55  18.151 - 
 Nonlab-B Threshold>30% $387.11  18.152 - 
 Nonlab-C Threshold>20% $416.12  18.156 - 
 Nonlab-D Threshold>10% $475.53  18.159 - 
 SCORE-A Threshold>7.5% $484.16  18.154 Strongly Dominated 
 SCORE-B Threshold>6.3% $489.01  18.154 Strongly Dominated 
 SCORE-C Threshold>4.6% $500.45  18.156 Strongly Dominated 
 SCORE-D Threshold>1.6% $532.96  18.158 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $369.70  18.150 - - 
Nonlab-A Threshold>40% $374.55  18.151 $4,821.13  - 
Nonlab-B Threshold>30% $387.11  18.152 $32,617.11  Weakly Dominated 
Nonlab-C Threshold>20% $416.12  18.156 $7,154.74  - 
Nonlab-D Threshold>10% $475.53  18.159 $16,063.61  - 
      Efficient Frontier (Nondominated 
Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $369.70  18.150 - 
 Nonlab-A Threshold>40% $374.55  18.151 $4,821.13  
 Nonlab-C Threshold>20% $416.12  18.156 $9,362.28  
 Nonlab-D Threshold>10% $475.53  18.159 $16,063.61  
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Table-A7-24: All event costs (acute and chronic) decreased by 25%, Women 
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $242.27  18.150 - 
 Nonlab-A Threshold>40% $249.99  18.151 - 
 Nonlab-B Threshold>30% $263.86  18.152 - 
 Nonlab-C Threshold>20% $296.12  18.156 - 
 Nonlab-D Threshold>10% $356.49  18.159 - 
 SCORE-A Threshold>7.5% $360.76  18.154 Strongly Dominated 
 SCORE-B Threshold>6.3% $366.60  18.154 Strongly Dominated 
 SCORE-C Threshold>4.6% $379.29  18.156 Strongly Dominated 
 SCORE-D Threshold>1.6% $413.24  18.158 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $242.27  18.150 - - 
Nonlab-A Threshold>40% $249.99  18.151 $7,678.60  - 
Nonlab-B Threshold>30% $263.86  18.152 $36,050.80  Weakly Dominated 
Nonlab-C Threshold>20% $296.12  18.156 $7,954.38  - 
Nonlab-D Threshold>10% $356.49  18.159 $16,321.63  - 
      Efficient Frontier (Nondominated 
Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $242.27  18.150 - 
 Nonlab-A Threshold>40% $249.99  18.151 $7,678.60  
 Nonlab-C Threshold>20% $296.12  18.156 $10,390.28  




	   55	  
Table-A7-25: Utility increased by 25%, Women 
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $306.02  18.189 - 
 Nonlab-A Threshold>40% $312.31  18.189 - 
 Nonlab-B Threshold>30% $325.52  18.189 Strongly Dominated 
 Nonlab-C Threshold>20% $356.15  18.192 - 
 Nonlab-D Threshold>10% $416.05  18.194 - 
 SCORE-A Threshold>7.5% $422.50  18.191 Strongly Dominated 
 SCORE-B Threshold>6.3% $427.84  18.191 Strongly Dominated 
 SCORE-C Threshold>4.6% $439.91  18.192 Strongly Dominated 
 SCORE-D Threshold>1.6% $473.14  18.193 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $306.02  18.189 - - 
Nonlab-A Threshold>40% $312.31  18.189 $23,541.17  Weakly Dominated 
Nonlab-C Threshold>20% $356.15  18.192 $19,320.02  - 
Nonlab-D Threshold>10% $416.05  18.194 $23,081.09  - 
      Efficient Frontier (Nondominated 
Strategies)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $306.02  18.189 - 
 Nonlab-C Threshold>20% $356.15  18.192 $19,764.26  
 Nonlab-D Threshold>10% $416.05  18.194 $23,081.09  
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Table-A7-26: Utility decreased by 25%, Women   
All Strategies          
 Strategy  Threshold Costs QALYs Dominance  
 Special No treatment $306.02  13.612 - 
 Nonlab-A Threshold>40% $312.31  13.613 - 
 Nonlab-B Threshold>30% $325.52  13.613 - 
 Nonlab-C Threshold>20% $356.15  13.615 - 
 Nonlab-D Threshold>10% $416.05  13.617 - 
 SCORE-A Threshold>7.5% $422.50  13.614 Strongly Dominated 
 SCORE-B Threshold>6.3% $427.84  13.614 Strongly Dominated 
 SCORE-C Threshold>4.6% $439.91  13.615 Strongly Dominated 
 SCORE-D Threshold>1.6% $473.14  13.616 Strongly Dominated 
 
      Strongly Dominated Strategies Removed        
Strategy  Threshold Costs QALYs ICER Dominance  
Special No treatment $306.02  13.612 - - 
Nonlab-A Threshold>40% $312.31  13.613 $9,953.68  - 
Nonlab-B Threshold>30% $325.52  13.613 $183,856.57  Weakly Dominated 
Nonlab-C Threshold>20% $356.15  13.615 $11,971.65  - 
Nonlab-D Threshold>10% $416.05  13.617 $31,067.43  - 
      Efficient Frontier (Nondominated Strrat)       
 Strategy  Threshold Costs QALYs ICER 
 Special No treatment $306.02  13.612 - 
 Nonlab-A Threshold>40% $312.31  13.613 $9,953.68  
 Nonlab-C Threshold>20% $356.15  13.615 $16,668.15  
 Nonlab-D Threshold>10% $416.05  13.617 $31,067.43  
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Table-A7-27: Statin compliance in all years equal to 1, Women  
All Strategies          
Strategy  Threshold Costs QALYs Dominance  
Special No treatment $306.02  18.150 - 
Nonlab-A Threshold>40% $312.04  18.152 - 
Nonlab-B Threshold>30% $324.33  18.155 - 
Nonlab-C Threshold>20% $356.73  18.161 - 
SCORE-A Threshold>7.5% $422.08  18.156 Strongly Dominated 
Nonlab-D Threshold>10% $425.65  18.167 - 
SCORE-B Threshold>6.3% $427.85  18.156 Strongly Dominated 
SCORE-C Threshold>4.6% $440.88  18.159 Strongly Dominated 
SCORE-D Threshold>1.6% $478.86  18.166 Strongly Dominated 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
Special No treatment $306.02  18.150 - 
Nonlab-A Threshold>40% $312.04  18.152 $2,682.94  
Nonlab-B Threshold>30% $324.33  18.155 $4,328.06  
Nonlab-C Threshold>20% $356.73  18.161 $5,311.88  
Nonlab-D Threshold>10% $425.65  18.167 $11,557.97  
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Table-A7-28: Uncalibrated Model, Women  
All Strategies          
Strategy  Threshold Costs QALYs Dominance  
Special No treatment $343.70  18.060 - 
Nonlab-A Threshold>40% $349.98  18.069 - 
Nonlab-B Threshold>30% $362.55  18.069 Strongly Dominated 
Nonlab-C Threshold>20% $393.01  18.075 - 
Nonlab-D Threshold>10% $450.30  18.083 - 
SCORE-A Threshold>7.5% $457.37  18.067 Strongly Dominated 
SCORE-B Threshold>6.3% $463.73  18.066 Strongly Dominated 
SCORE-C Threshold>4.6% $475.44  18.074 Strongly Dominated 
SCORE-D Threshold>1.6% $507.36  18.075 Strongly Dominated 
     Efficient Frontier (Nondominated Strategies)       
Strategy  Threshold Costs QALYs ICER 
Special No treatment $343.70  18.060 - 
Nonlab-A Threshold>40% $349.98  18.069 $718.07  
Nonlab-C Threshold>20% $393.01  18.075 $6,800.07  
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